Pneumonia due to Pneumocystis carinii is an infrequent complication following autologous stem cell transplantation (ASCT) which is associated with a high mortality. Although administration of trimethoprim/sulfamethoxazole (TMP/SMX) is an effective prophylactic strategy for Pneumocystis carinii pneumonia (PCP), treatment-associated toxicity frequently results in discontinuation of therapy. We have conducted a prospective randomized trial comparing atovaquone, a new anti-Pneumocystis agent, with TMP/SMX for PCP prophylaxis following autologous peripheral blood stem cell (PBSC) transplantation. Thirty-nine patients were studied. Twenty patients received atovaquone suspension and 19 patients received TMP/SMX. The median ages were 44 (range 20-68) and 47 (range 32-63) years, respectively. A similar number of patients with solid tumors (14 vs 15) and hematologic malignancies (five vs five) were treated in each group. Either TMP/SMX (160/800 mg) or atovaquone (1500 mg) was administered daily from transplant day −5 until day −1, discontinued from day 0 to engraftment, then resumed 3 days per week until day +100 post-transplant. The median time to engraftment (ANC Ͼ0.5 × 10 9 /l) was similar in both groups. Eighty percent of the patients randomized to atovaquone prophylaxis completed the study. Four atovaquone-treated patients were removed from study; two patients (10%) did not receive a transplant and two patients (10%) were removed due to a protocol violation. None of the 16 patients treated with atovaquone experienced treatment-associated adverse effects. Of the 19 patients randomized to receive TMP/SMX, 55% completed the study. Nine TMP/SMX-treated patients were removed from the study; one patient (5%) did not receive a transplant and eight patients (40%) were removed due to drug intolerance (P Ͻ 0.003). The rate of intolerance to TMP/SMX led to the early discontinuation of this randomized trial. Intolerance of TMP/SMX included elevated transaminase levels 
(n = 1), nausea or vomiting (n = 3), thrombocytopenia (n = 2) and neutropenia (n = 2). All episodes of TMP/SMP intolerance occurred following transplantation after a median duration of 17.5 (range 2-48) days and a median of 7 (range 1-20) doses. Resolution of adverse side-effects occurred in all eight patients within a median of 7 (range 2-20) days following discontinuation of therapy. Neither PCP nor bacterial infections were identified in any of the patients treated. This prospective randomized study demonstrated that atovaquone is well-tolerated for anti-Pneumocystis prophylaxis in autologous PBSC transplant patients intolerant of TMP/SMX. Keywords: atovaquone; Pneumocystis carinii pneumonitis; autologous PBSC transplantation; prophylaxis; toxicity Pneumocystis carinii pneumonia (PCP) is a common infection in immunocompromized individuals, especially those treated with corticosteroids. A small number of patients may develop PCP following autologous bone marrow transplantation. [1] [2] [3] [4] Trimethoprim-sulfamethoxazole (TMP/SMX) is the preferred prophylactic agent for PCP. While effective in the prevention of PCP, approximately 30% to 40% of treated patients discontinue therapy due to drug intolerance. 5, 6 Common adverse effects which may result in drug withdrawal include skin rash, myelosuppression, nausea, fever and renal and liver toxicity. 3 Tuan and colleagues 2 reported a high PCP-related mortality in patients who had undergone either allogeneic or autologous bone marrow transplantation and who had discontinued TMP/SMX prophylaxis due to adverse events. Although inferior to TMP/SMX, dapsone and intravenous (i.v.) or aerosolized pentamidine are accepted alternative therapies available for PCP prophylaxis for PBSC transplant recipients. [7] [8] [9] However, TMP/SMX intolerance may predict intolerance of dapsone, making dapsone a less desirable option. 10 Prophylactic therapy with i.v. or aerosolized pentamidine, while better tolerated, may be associated with multiorgan toxicity including alterations in glucose metabolism 9, 11 and has been associated with atypical breakthrough infections. 12 Aerosolized pentamidine also requires experienced personnel for administration and careful patient monitoring. Atovaquone is a new anti-Pneumocystis agent, thought to act as a selective inhibitor of the mitochondrial electron transport in a number of parasitic protozoa. 13 It has been FDA approved for the treatment of mild to moderately severe PCP in TMP/SMX intolerant patients. In a comparison trial of atovaquone tablets and TMP/SMX for the treatment of PCP in AIDS patients, atovaquone was found to be less effective than TMP/SMX, but was associated with fewer treatment-limiting adverse events (9% vs 24%, respectively).
14 In another comparative PCP treatment study, oral atovaquone was reported to be equally effective as intravenous pentamidine, and was better tolerated. 15 Treatment-limiting adverse events were more frequent in the pentamidine group than in the atovaquone group, 41% vs 7% respectively (P Ͻ 0.001). The most common side-effect was rash in 4% of patients. Headache, GI intolerance and fever were seen in less than 1%. Generally, adverse side-effects associated with atovaquone are mild and have not required discontinuation of the drug.
Comparative trials of atovaquone and TMP/SMX for PCP prophylaxis are lacking, primarily due to the large sample size necessary for such a study. Thus the experience with atovaquone as a PCP prophylactic agent is limited and non-existent in the BMT population. However, since atovaquone has been shown to be an effective second line therapy for PCP and well tolerated with a low incidence of adverse side-effects, it may also serve as a useful prophylactic agent as well.
A prospective, randomized, open label trial was conducted to evaluate the safety and tolerability of atovaquone as an alternative prophylactic therapy for PCP following autologous peripheral blood stem cell transplantation.
Patients and methods

Patients
Forty-six of 54 consecutive adult patients undergoing autologous PBSC transplantation for hematologic and solid malignancies were eligible and 39 were enrolled in the study between January 1997 and December 1997. Seven patients were ineligible due to the presence of a sulfa allergy, and one patient was admitted with ongoing prophylactic TMP/SMX for urinary tract infections. Of the seven patients who chose not to participate four were participating in another transplant companion trial. Enrolled patients were randomized to receive either TMP/SMX (160 mg/800 mg p.o. every day) or atovaquone (1500 mg p.o. every day). By virtue of having fulfilled the eligibility criteria for an autologous transplant protocol, these patients did not have significant underlying cardiac, pulmonary, hepatic or renal disease. Exclusion criteria included an allergy to sulfa or a history of intolerance of TMP/SMX or atovaquone. The study was approved by the Subcommittee for Human Studies at the Massachusetts General Hospital and all patients provided written informed consent. The primary endpoint of this study was the evaluation of treatment-limiting toxicities (TLT) associated with atovaquone vs TMP/SMX for PCP prophylaxis. A secondary endpoint was the assessment of the incidence of late bacterial and fungal infection following autologous PBSC transplant. Due to the statistically higher incidence of toxicity associated with TMP/SMX seen after evaluation of the first 38 of 70 planned patients the study was terminated early.
All patients received peripheral blood stem cells as their source of autologous stem cell support. PBSC were cryopreserved and thawed at the bedside immediately prior to infusion on day 0. For patients enrolled in an interleukin-2 (IL-2) (Chiron, Dover, DE, USA) activated PBSC protocol, cryopreserved cells were thawed and incubated in the presence of IL-2 for 24 h prior to infusion. The assignment of transplant conditioning regimen was based on the underlying disease state. Most patients received a high-dose Carbo/Cy-based regimen (carboplatin 600 mg/m 2 for 3 days and cyclophosphamide 2000 mg/m 2 for 3 days) ( Table 1) .
Supportive care
All patients were treated in HEPA-filtered rooms and received antimicrobial prophylaxis. Broad-spectrum antibiotic therapy was initiated if a single temperature reading of greater than 38.0°C was recorded. Irradiated leukofiltered packed RBCs and platelets were transfused to maintain a hematocrit greater than 25% and a platelet count greater than 20 × 10 9 /l.
Pneumocystis carinii pneumonia prophylaxis
Regimens for the prevention of Pneumocystis carinii pneumonia were trimethoprim-sulfamethoxazole (TMP/SMX) (Bactrim; GlaxoWelcome Triangle Park, NC, USA) two single strength tablets (160/800 mg) or atovaquone suspension (Mepron; Glaxo Welcome) two teaspoons (1500 mg) Ca = carcinoma; NHL = non-Hodgkin's lymphoma; HD = Hodgkin's disease; MM = multiple myeloma; Carbo = carboplatin; CY = cyclophosphamide; Tax = paclitaxal (Taxol); IL-2 = interleukin 2; BU = busulfan; PBSCT = peripheral blood stem cell transplant; TBI = total body irradiation; NS = not significant. daily from transplant day −5 to day −1. Since ingestion of food, in particular fat, has been shown to enhance atovaquone absorption significantly, all of our patients were instructed to take atovaquone with a meal. Due to the potential myelosuppressive properties of TMP/SMX, both prophylaxis regimens were discontinued on day −1. The PCP prophylactic regimens were then resumed 3 days per week (Monday, Wednesday and Friday) following resolution of neutropenia (ANC у0.5 × 10 9 cells/l) until day +100 post-transplant. Study drug was discontinued following engraftment if: (1) the patient experienced a significant fall in WBC and/or ANC (drop in the ANC to less than 0.5 × 10 9 /l, a fall to Ͻ1.0 × 10 9 /l in a patient who had achieved an ANC Ͻ1.0 × 10 9 /l or an unexplained fall in total WBC to Ͻ2.0 × 10 9 /l on 2 consecutive weekly determinations in patients who had previously achieved a total WBC Ͼ2.0 × 10 9 /l); (2) blood chemistries revealed an elevation in liver transaminase levels (ALT, AST), alkaline phosphatase or a total bilirubin to greater than 2 times baseline (pre-PCP prophylaxis level), nausea and or vomiting for at least 3 consecutive treatment days which was refractory to anti-emetics and unexplained by other causes; (3) an unexplained skin rash or allergic reaction of any kind. study drug was discontinued in patients if any other adverse event was experienced that could not be reasonably attributed to another cause, and was believed to be possibly attributed to the study medication. Patients removed from the study were treated with monthly i.v. pentamidine. Clinical status and abnormal laboratory values requiring the discontinuation of study medication were re-assessed within 7 days to verify resolution of any abnormality.
Evaluation
Hospitalized patients were monitored daily with complete blood counts, electrolytes, liver function tests, blood urea nitrogen and creatinine. Patients were monitored for nausea, vomiting, diarrhea and other toxicity. Following engraftment, patients were discharged from the hospital and followed in the outpatient clinic until transfusion independent (approximately day +30). The patients were then referred back to their primary oncologist, who was informed by a letter of their patient's continued participation in the study until day +100 following transplantation and was asked to monitor the patient bimonthly for signs of drug toxicity (with complete blood counts and liver function tests) and for infections. Information provided by followup visits on clinical status and hematologic and hepatic function was recorded and reviewed at our center on a twice a month schedule until day +100. Compliance with PCP prophylactic drug therapy was assessed during patient follow-up visits and telephone calls to the patient between transplant day +40 and day +80.
Statistical analysis
Primary analyses of the study measurements were performed with the intent-to-treat rule, ie, including all randomized patients who proceed to transplant. Wilcoxon rank-sum test was used to examine differences between measured endpoint values and changes from baseline. Fisher's exact tests were used to compare proportions. The primary outcome was treatment-limiting toxicity within 100 days post-autologous transplantation, and all patients were followed for at least 100 days.
Results
Patients
Thirty-nine eligible patients were entered and randomized in the study. Nineteen patients were randomized to receive TMP/SMX and 20 patients were randomized to receive atovaquone suspension. Detailed patient characteristics are shown in Table 1 . There were no statistically significant differences in patient or treatment characteristics between the two groups.
One of the 19 patients randomized to receive TMP/SMX treatment and two patients randomized to receive atovaquone treatment were determined not to be transplant candidates (Table 2 ). Of the 18 transplanted patients randomized to the atovaquone, two patients were removed from the study due to the failure to initiate atovaquone therapy beginning on transplant day −5. One patient began therapy from day −3 pre-transplant, the second received only post-transplant therapy. However, we chose to base all statistical analyses conservatively on the 16 transplanted patients receiving the full prophylactic regimen. We felt this was acceptable since including these two patients would serve only to further strengthen our findings.
Engraftment
There was no difference in the times to engraftment between the two groups. The median time to neutrophil recovery (ANC Ͼ0.5 × 10 9 /l) was 9 (range 7-12) days in both groups, and platelet recovery (Ͼ20 × 10 9 /l) was 11 (range 7-16) days and 11 (range 7-35) days for TMP/SMX and atovaquone-treated patients, respectively. There was no documented bacterial infection in any of the study patients and none of the patients developed PCP.
Treatment intolerance
Of the transplanted patients receiving atovaquone prophylaxis none were removed from the study due to toxicity. Eight patients receiving TMP/SMX prophylaxis, required discontinuation of drug therapy due to intolerance (P = 0.003) ( Table 2 ). All episodes of TMP/SMX intolerance following transplantation occurred after a median duration of 17.5 (range 3-48) days after reinstitution of therapy, and a median of 7 (range 1-20) TMP/SMX doses. Resolution of all adverse effects occurred following discontinuation of the study drug (median of 7 (range 2-20) days).
The reasons for the discontinuation of TMP/SMX PCP prophylaxis included: an elevated aspartate aminotransferase (AST) level (24 U/l to 67 U/l) in one patient (5%) within 18 days after resuming prophylactic TMP/SMX. Three patients (15%) experienced gastrointestinal intolerance with nausea and/or vomiting (4, 4 and 17 days after resuming study medication). Four (20%) patients experienced hematologic toxicity. Two patients had a fall in WBC. In one patient, the WBC fell from 8 × 10 9 /l to 2 × 10 9 /l over 37 days and in the other case, from 4.5 × 10 9 /l to 2 × 10 9 /l 10 days after resuming TMP/SMX therapy. Two patients had an unexplained decrease in the platelet count, which was attributed to the study medication. In one case, a 70% decline (141 × 10 9 /l to 42 × 10 9 /l) was seen within 24 days and in the other case, a 30% drop (80 × 10 9 /l to 55 × 10 9 /l) was seen 19 days after resuming TMP/SMX therapy. No other medication changes were introduced and platelet counts recovered 10 and 6 days after stopping TMP/SMX. Although thrombocytopenia was not a specified drug withdrawal criterion, no other attributing therapy could be identified. Removal of these two patients from the toxicity analysis did not abdicate the significant difference found between the two groups.
Follow-up
The regimen compliance and toxicity was assessed during six post-transplant follow-up visits to day +100 (Table 3) . Ten TMP-SMX-treated patients and 16 atovaquone-treated patients who were not removed from the study due to drug Table 3 Study follow-up intolerance, completed at least four of the six requested follow-up visits within a median 96.8 days (TMP/SMX) and 93.5 days (atovaquone), respectively. Four atovaquoneand two TMP/SMX-treated patients completed all six post transplant follow-up visits. Telephone contact was made to each patient's home during the follow-up period (days 40 to 80). Patients were asked about therapy compliance and adverse effects (ie gastrointestinal complaints or rashes). One patient from each group reported missing one medication dose. One atovaquone-treated patient who completed all six follow-up visits and who had been treated for depression in the pre-transplant period discontinued all medication including atovaquone for a period of 24 days (day +56 to day +80). Atovaquone therapy was resumed on day +80 and continued to day +100. Inclusion or exclusion of this study patient did not alter analysis of these data.
Discussion
This is the first randomized study evaluating the safety and tolerance of atovaquone for PCP prophylaxis following autologous peripheral blood stem cell transplantation. Although the incidence of PCP in this population is low, documented pulmonary infection with Pneumocystis carinii is associated with significant mortality suggesting the importance of appropriate prophylaxis in this group. Trimethoprim/sulfamethoxazole is the drug of choice for both prophylaxis and treatment of PCP; unfortunately, the high incidence of adverse side-effects often results in the discontinuation of therapy. This study has demonstrated that atovaquone is better tolerated than TMP/SMX and may prove to be a useful alternative for PCP prophylaxis for patients who are intolerant of TMP/SMX.
The common toxicities of atovaquone in prophylaxis and treatment trials have included rash (up to 4%), headache and gastrointestinal disturbances. 14, [16] [17] [18] Hematologic toxicity was uncommon. 17 Atovaquone tablets, used in earlier studies, have been discontinued due to poor bioavailability. Significantly improved bioavailability has been achieved with a new reformulated atovaquone suspension. The present study utilized the atovaquone suspension at a dose of 1500 mg daily pre-transplant then three times a week post-transplant. One might expect with improved bioavailability to see potentially greater toxicity. 14, 19 However, none of the patients receiving atovaquone developed treatment-limiting complication.
By contrast, rash and hematologic toxicity are common in TMP/SMX therapy. Rash was not observed in the study patients but treatment-limiting neutropenia and thrombocytopenia (20%) and gastrointestinal toxicity (nausea and vomiting in 15%, liver function test abnormality in 5%) were observed. The incidence of various forms of toxicity is comparable to those found in larger populations of AIDS patients receiving TMP/SMX. 14, 17, 20, 21 All treatment-limiting events in the TMP/SMX group were reversible following drug withdrawal; resolution was seen in all patients within a median of 7 (range 2-20) days. Following autologous PBSC transplantation the majority of patients are discharged receiving PCP prophylactic therapy alone. In our series nine of the study patients (three atovaquone and six TMP/SMX) were also treated with IL-2 and pentoxifylline, a known emetogenic agent. None of the atovaquone patients co-treated with pentoxifylline experienced an adverse event. Two of the three patients who discontinued TMP/SMX due to nausea and vomiting were also receiving pentoxifylline. In one case, the nausea preceded the introduction of pentoxifylline. In the other, intractable nausea resulted in the discontinuation of both agents. Although the patient population is small, these observations suggest that TMP/SMX gastrointestinal toxicity may be additive to that of other agents. Patients co-treated with other emetogenic agents may benefit from the availability of alternative prophylactic agents such as atovaquone.
Patient compliance was carefully monitored through direct patient contact and follow-up visits throughout the trial. Although pharmacokinetic studies have shown a direct correlation between efficacy and the steady-state plasma concentration, 16 steady-state plasma atovaquone concentrations were not studied in the study population. However, in a small series of solid organ transplant patients at this center adequate atovaquone serum levels (levels exceeding the MIC for P. carinii) were achieved after a prophylactic dosing regimen of 1500 mg daily of atovaquone. 22 Patients were sent home from the hospital with enough study drug to complete the 100 day treatment period. Compliance was monitored by direct patient contact and through the referring physician until day +100. Compliance with the three times a week regimen was very high in both groups of patients. Although no patient in either treatment arm developed PCP during the study period, our study was designed only to evaluate toxicity and safety. Since there is low incidence of PCP in our population following transplant a prospective trial to evaluate the efficacy of this atovaquone PCP prophylactic dosing regimen would require a much larger population than studied here. What we have shown is that atovaquone suspension regimen in our population is well tolerated and associated with a high degree of compliance.
No documented bacterial infections were identified in either group. A potential advantage in the use of TMP/SMX, however, is in the prevention of common bacterial infections in the immunocompromised host. Such infections in the autologous PBSC transplant patient are unusual, however. Virtually all of the infections that have occurred in our patient population have occurred while patients were taking TMP/SMX prophylaxis and have been catheter related.
